The in vivo formation of fructosamines following non-enzymatic reaction of proteins with glucose (i.e. glycation) was first described almost 30 years ago. Until recently, the only known fate of fructosamines in mammalian cells was their spontaneous conversion into advanced glycation end products. The identification in human erythrocytes of a new enzyme, fructosamine 3-kinase, disclosed the existence of a so-far unsuspected intracellular metabolism of these compounds. Fructosamine 3-kinase phosphorylates with high affinity both low-molecular-mass and protein-bound fructosamines on the third carbon of their deoxyfructose moiety, leading to the formation of fructosamine 3-phosphates. The latter are unstable and spontaneously decompose into inorganic phosphate and 3-deoxyglucosone, with concomitant regeneration of the unglycated amine. The presence of proteins related to fructosamine 3-kinase in many prokaryotic and eukaryotic genomes suggests that this 'deglycation' process is not restricted to mammals.
Fructosamines: formation, role in diabetes and metabolism
Fructosamines are the result of a spontaneous condensation between glucose and primary amines, followed by an Amadori rearrangement [1] . The most famous glycated protein is HbA1c, a form of haemoglobin bearing fructosamine residues at the N-terminal valine of its β-chains, and which represents approx. 5% of total haemoglobin in normal individuals [2] . It is noteworthy that protein modification by glucose usually mostly affects the ε-amino group of lysyl residues, since the N-terminal end of many eukaryotic cytosolic proteins is blocked by acetylation [3, 4] . Glycated haemoglobin may therefore be considered as an exception to this rule, since approximately 50% of the fructosamine residues are contributed by modified β-N-terminal ends, the other 50% being bound to lysyl side chains [5] . Molecules other than proteins, such as aminophospholipids, can also undergo glycation [6] .
Protein glycation is of importance with respect to diabetes for two reasons. First, since the reaction rate is low and directly proportional to glucose concentration [7, 8] , the levels of glycated haemoglobin and serum fructosamines are an integrated measure of the blood glucose concentration over time, and are therefore commonly assayed to assess efficacy of treatment [9] [10] [11] . Secondly, fructosamines may undergo further spontaneous reactions, yielding AGEs (advanced glycation end products). Both fructosamines [12] and AGEs Key words: Amadori compound, complications, diabetes, glycation, fructose 3-phosphate, protein repair. Abbreviations used: AGE, advanced glycation end product; DMF, 1-deoxy-1-morpholinofructose; FN3K, fructosamine 3-kinase; FN3P-Hb, haemoglobin bound to a fructosamine 3-phosphate group; fructoseglycine, N ε -(1-deoxyfructosyl)glycine; fructoselysine, N ε -(1-deoxyfructosyl)lysine; fructosevaline, N ε -(1-deoxyfructosyl)valine. 1 To whom correspondence should be addressed (e-mail vanschaftingen@bchm.ucl.ac.be).
(reviewed in [13] [14] [15] ) are probably involved in the development of diabetic complications.
The glycation process has long been considered as irreversible, although, retrospectively, some early findings may have suggested the existence of an intracellular deglycation mechanism. Schleicher and Wieland [16] predicted the halflife of proteins by comparing their rate of in vitro glycation with their extent of in vivo glycation. This method should provide correct values provided that glycation is a purely spontaneous (chemical) process and there is no enzymatic deglycation. The predicted half-lives fitted with accepted values in the case of extracellular proteins such as albumin, but not for haemoglobin, for which the glycation-derived value was much shorter than the average life-span of human erythrocytes (13.6 compared with 120 days). Along the same lines, Shapiro et al. [5] demonstrated that the prevalent sites of glycation of haemoglobin in vivo differ from those obtained after incubation of this protein with glucose in vitro. The authors hypothesized that this discrepancy could be due to the fact that glycation is affected by the composition of the intracellular milieu, or that fructosamine residues can undergo 'enzymatic modifications'.
Different kinds of enzymes enable some micro-organisms to metabolize fructosamines. Amadoriases are oxidases that cleave either the keto-amino or the alkyl-amino bond of these compounds, producing respectively glucosone and a free amine [17, 18] , or free fructosamine and an aldehyde [19] . In Escherichia coli, a specific kinase has recently been identified and shown to convert free fructoselysine [N ε -(1-deoxyfructosyl)lysine] into fructoselysine 6-phosphate, which is then cleaved by a specific 'deglycase' to yield lysine and glucose 6-phosphate [20] . All of these microbial enzymes act only on low-molecular-mass fructosamines and not on protein-bound residues, and therefore do not participate in protein deglycation. Furthermore, no such enzymes are found in mammalian cells.
A model fructosamine inhibits the formation of fructose 3-phosphate in human erythrocytes
The starting point for the identification of a deglycation pathway in mammalian cells was the discovery of fructose 3-phosphate in human erythrocytes [21] . This unusual phosphate ester is formed from fructose in erythrocytes by a 'fructose 3-kinase', which displays a very low affinity for its substrate (apparent K m of approx. 30 mM) [22] . The V max of fructose 3-phosphate formation in erythrocytes is approx. 0.25 µmol · h −1 · ml −1 of packed cells [23] , which is at least two orders of magnitude lower than the rate of glycolysis in human erythrocytes. Another point is that no enzyme is known to metabolize fructose 3-phosphate, accounting for its accumulation in cells incubated with high concentrations of fructose [22] . These considerations argued against a role of 'fructose 3-kinase' in fructose metabolism, and led us to postulate that the physiological substrate of this kinase was not fructose itself, but compounds with a closely related structure, possibly fructosamines. This was further supported by an abstract suggesting the presence in human erythrocytes of a kinase acting on fructose and glycated histones [24] .
We tested this hypothesis by investigating the effect of a model fructosamine, DMF (1-deoxy-1-morpholinofructose), on the formation of fructose 3-phosphate in intact human erythrocytes. Figure 1 shows that these cells accumulate large amounts of fructose 3-phosphate when incubated with 50 mM fructose, and that DMF strongly inhibits this accumulation, with an apparent K i of approx. 100 µM.
31 P-NMR analysis showed not only that DMF inhibited fructose phosphorylation, but that it was itself phosphorylated. The attachment of the phosphate group to the third carbon of the deoxyfructose moiety of DMF was demonstrated by tandem MS and NMR analysis of the phosphorylated compound isolated from erythrocytes incubated in the presence of this fructosamine [23] . Synthesis of radiolabelled [ 14 C]DMF permitted us to calculate an apparent K m of approx. 100 µM for DMF 3-phosphate formation. This value is identical to the K i of the inhibition exerted by this fructosamine on fructose phosphorylation. Since the kinase acting on fructose and DMF has a much higher affinity (approx. 300-fold) for the model fructosamine than for the ketose, its designation as 'fructosamine 3-kinase' (FN3K) appeared to be fully justified.
Cloning and heterologous expression of human and mouse FN3Ks
FN3K was purified to near homogeneity from human erythrocytes, taking advantage of its strong affinity for Blue Sepharose. The activity co-purified with a polypeptide of approx. 35 kDa on SDS/polyacrylamide gels. This candidate was isolated, digested with trypsin and submitted to tandem MS. The sequence of one tryptic peptide obtained in this way allowed the identification of human and mouse ESTs (expressed sequence tags) encoding proteins of unknown function, and enabled us to reconstruct and clone the cDNAs of putative human and mouse FN3Ks [25] .
The corresponding proteins were expressed in Escherichia coli and purified, and their kinetic properties were compared with those of the purified 'natural' enzyme. The three enzymes phosphorylate DMF and the glycated ε-amino group of free lysine or of lysyl residues within lysozyme, with Proteins sharing approx. 30% identity with FN3K are present in several prokaryotic and eukaryotic genomes, although not in those of Drosophila melanogaster and Saccharomyces cerevisiae. An alignment of some of these proteins with human and mouse FN3Ks is shown in Figure 2 . A conserved motif located towards the C-terminal end, i.e. PXLXHGDLWSXN, appears to be shared by all these proteins. Interestingly, some residues (HGDXXXXN) of this motif are also highly conserved in aminoglycoside kinases [27] , which, like FN3K, transfer a phosphoryl group on to a secondary alcohol nearby an amino group.
Role of fructosamine phosphorylation
Intracellular glycated proteins are physiological substrates of FN3K, as demonstrated by the identification of fructoselysine 3-phosphate bound to haemoglobin using 31 P-NMR [26]. The significance of this phosphorylation was elucidated by studying the effect of DMF, a substrate and competitive inhibitor of FN3K, on the level of glycated haemoglobin in human erythrocytes incubated ex vivo in the presence of 200 mM glucose [28] . Such a high concentration was needed to reach a level of glycated haemoglobin of approx. 13% in 2 days (compared with 5% in control cells incubated with 5 mM glucose), since the rate of fructosamine formation is first-order with respect to sugar concentration. Under these conditions of heavy glycation, a form of haemoglobin containing alkali-labile phosphate could be detected that accounted for approx. 5% of total haemoglobin. This amount was much lower if DMF was present in the incubation medium, indicating that alkali-labile phosphate corresponds to fructosamine 3-phosphate residues (FN3P-Hb, i.e. haemoglobin bound to a fructosamine 3-phosphate group). DMF in the medium also almost doubled the rate of accumulation of glycated haemoglobin, confirming that the latter is a substrate for FN3K in intact erythrocytes. When cells incubated for 48 h with 200 mM glucose were returned to a medium containing 5 mM glucose, the level of total glycated haemoglobin (i.e. the sum of glycated haemoglobin and FN3P-Hb) decreased only if DMF was omitted from the medium (Figure 3 ). This net decrease confirmed the presence of a FN3K-dependent deglycation process, rather than a mere phosphorylation/dephosphorylation cycle between glycated haemoglobin and FN3P-Hb. It can be seen in Figure 3 that the level of glycated haemoglobin in the absence of DMF did not return to the expected incubations were stopped and glycated haemoglobin was measured by affinity chromatography on boronate columns. FN3P-Hb corresponds to the alkali-labile phosphate released from a form of haemoglobin retained on anion-exchangers. Modified, with permission, from [28] . c The Biochemical Society.
background level of 5% during the second phase of incubation (after 48 h), indicating that some of the fructosamine residues are resistant to deglycation. A likely explanation is that some glycated residues, for instance the N-terminal valine of the β-chains, are poor substrates of FN3K and undergo only slow deglycation, while others (the ε-amine of lysines) are readily phosphorylated by this enzyme. This would be in agreement with the kinetic properties of the enzyme mentioned above.
In vitro, free fructoselysine 3-phosphate spontaneously decomposes into inorganic phosphate and 3-deoxyglucosone [26] , and this is most probably accompanied by regeneration of the unglycated ε-amine. [
14 C]Fructoselysine 3-phosphate labelled on its amino acid moiety spontaneously converts to a radioactive compound with the same chromatographic behaviour as lysine (G. Delpierre and E. Van Schaftingen, unpublished work). In the experiment shown in Figure 3 , the oxidation product of 3-deoxyglucosone, i.e. 2-keto-3-deoxygluconate, was assayed using a specific kinase from Escherichia coli [28] . The amount of 2-keto-3-deoxygluconate measured in the cells incubated for 48 h with 200 mM glucose and without DMF was found to match the amount of haemoglobin that underwent deglycation over the same period. Furthermore, the estimated half-life of FN3P-Hb in this experiment was close to the value determined in vitro for free fructoselysine 3-phosphate ( [26] ; G. Delpierre and E. Van Schaftingen, unpublished work), suggesting an identical degradation mechanism for both protein-bound and lowmolecular-mass fructosamine 3-phosphates.
Conclusion
Phosphorylation of fructosamine residues on their third carbon appears to be a means by which these residues are removed from protein. FN3K appears therefore to catalyse a new protein repair mechanism. Other protein repair mechanisms allow, e.g., the reduction of methionine sulphoxide residues to methionine, or the conversion of L-isoaspartyl residues to L-aspartyl, and their importance has been underlined by mouse knock-out experiments [29, 30] . Further work is needed to evaluate the impact of the absence of FN3K. It will also be most interesting to know if the related genes found in different species exert a similar activity to strive against 'sugar stress'.
